| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Islets of Langerhans Transplantation | 45 | 2023 | 225 | 16.570 |
Why?
|
| Pancreatitis, Chronic | 12 | 2023 | 49 | 5.180 |
Why?
|
| Islets of Langerhans | 21 | 2021 | 544 | 4.780 |
Why?
|
| Pancreatectomy | 19 | 2023 | 148 | 4.770 |
Why?
|
| Diabetes Mellitus, Type 1 | 17 | 2023 | 567 | 3.620 |
Why?
|
| T-Lymphocytes, Regulatory | 12 | 2016 | 295 | 2.880 |
Why?
|
| Insulin | 17 | 2023 | 1160 | 1.970 |
Why?
|
| Insulin-Secreting Cells | 13 | 2021 | 397 | 1.930 |
Why?
|
| Transplantation, Autologous | 17 | 2023 | 330 | 1.880 |
Why?
|
| Blood Glucose | 12 | 2021 | 873 | 1.730 |
Why?
|
| Vascularized Composite Allotransplantation | 2 | 2021 | 13 | 1.590 |
Why?
|
| C-Peptide | 9 | 2021 | 174 | 1.330 |
Why?
|
| Fasting | 2 | 2018 | 161 | 1.250 |
Why?
|
| Pancreas | 8 | 2018 | 239 | 1.150 |
Why?
|
| Diabetes Mellitus, Experimental | 6 | 2018 | 190 | 1.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2016 | 425 | 0.940 |
Why?
|
| Sulfonamides | 2 | 2023 | 300 | 0.930 |
Why?
|
| Transplant Recipients | 2 | 2021 | 122 | 0.890 |
Why?
|
| Humans | 75 | 2023 | 86617 | 0.870 |
Why?
|
| Receptors, Interleukin-8A | 2 | 2021 | 4 | 0.860 |
Why?
|
| Receptors, Interleukin-8B | 2 | 2021 | 5 | 0.860 |
Why?
|
| Immunosuppressive Agents | 4 | 2021 | 977 | 0.860 |
Why?
|
| Composite Tissue Allografts | 1 | 2021 | 7 | 0.840 |
Why?
|
| Forkhead Transcription Factors | 6 | 2016 | 166 | 0.800 |
Why?
|
| Cell Separation | 3 | 2020 | 196 | 0.790 |
Why?
|
| Fatty Liver | 1 | 2021 | 125 | 0.710 |
Why?
|
| Biological Products | 1 | 2021 | 143 | 0.670 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2019 | 108 | 0.650 |
Why?
|
| Organ Transplantation | 1 | 2022 | 265 | 0.640 |
Why?
|
| Donor Selection | 2 | 2018 | 67 | 0.630 |
Why?
|
| Diabetes Mellitus | 5 | 2021 | 806 | 0.620 |
Why?
|
| Tissue and Organ Procurement | 1 | 2022 | 311 | 0.620 |
Why?
|
| Male | 36 | 2023 | 40958 | 0.610 |
Why?
|
| Middle Aged | 23 | 2021 | 25017 | 0.610 |
Why?
|
| Adult | 27 | 2023 | 25640 | 0.600 |
Why?
|
| Hypoglycemic Agents | 2 | 2017 | 378 | 0.600 |
Why?
|
| Surgical Wound Infection | 1 | 2019 | 184 | 0.590 |
Why?
|
| Leukapheresis | 1 | 2016 | 19 | 0.590 |
Why?
|
| Pain, Postoperative | 2 | 2018 | 240 | 0.560 |
Why?
|
| Graft Survival | 3 | 2018 | 884 | 0.550 |
Why?
|
| Cell Culture Techniques | 2 | 2014 | 188 | 0.540 |
Why?
|
| Liver Transplantation | 3 | 2021 | 1268 | 0.540 |
Why?
|
| Tissue Preservation | 1 | 2015 | 14 | 0.530 |
Why?
|
| Transplantation Tolerance | 3 | 2011 | 130 | 0.500 |
Why?
|
| Universities | 1 | 2015 | 135 | 0.490 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 3636 | 0.480 |
Why?
|
| Body Height | 1 | 2014 | 99 | 0.480 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 645 | 0.470 |
Why?
|
| Female | 28 | 2023 | 44509 | 0.460 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2013 | 52 | 0.460 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2013 | 6 | 0.460 |
Why?
|
| Ikaros Transcription Factor | 1 | 2013 | 25 | 0.450 |
Why?
|
| Quality of Life | 3 | 2018 | 1583 | 0.440 |
Why?
|
| Cryopreservation | 1 | 2013 | 68 | 0.440 |
Why?
|
| United States | 7 | 2022 | 6665 | 0.430 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 5 | 2016 | 36 | 0.430 |
Why?
|
| Treatment Outcome | 12 | 2021 | 7990 | 0.420 |
Why?
|
| Adolescent | 13 | 2020 | 8979 | 0.410 |
Why?
|
| Immunologic Factors | 1 | 2013 | 170 | 0.410 |
Why?
|
| Pancreatitis | 3 | 2021 | 87 | 0.390 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 339 | 0.370 |
Why?
|
| Interferon-gamma | 2 | 2011 | 444 | 0.370 |
Why?
|
| Child | 11 | 2023 | 6926 | 0.350 |
Why?
|
| Young Adult | 9 | 2020 | 5974 | 0.350 |
Why?
|
| Prospective Studies | 7 | 2023 | 4212 | 0.330 |
Why?
|
| DNA, Catalytic | 1 | 2007 | 2 | 0.320 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 4 | 2016 | 9 | 0.320 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2007 | 36 | 0.310 |
Why?
|
| Animals | 25 | 2021 | 26582 | 0.310 |
Why?
|
| Tunica Intima | 1 | 2007 | 59 | 0.310 |
Why?
|
| Vas Deferens | 1 | 2007 | 7 | 0.300 |
Why?
|
| Genital Diseases, Male | 1 | 2007 | 8 | 0.300 |
Why?
|
| Obesity | 2 | 2019 | 963 | 0.300 |
Why?
|
| Tissue Scaffolds | 3 | 2017 | 106 | 0.290 |
Why?
|
| Liver Neoplasms | 3 | 2021 | 736 | 0.290 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 449 | 0.290 |
Why?
|
| Surgical Mesh | 1 | 2007 | 116 | 0.270 |
Why?
|
| Hernia, Inguinal | 1 | 2007 | 67 | 0.270 |
Why?
|
| Time Factors | 6 | 2020 | 5209 | 0.250 |
Why?
|
| Registries | 3 | 2012 | 702 | 0.250 |
Why?
|
| Rats | 11 | 2017 | 3990 | 0.240 |
Why?
|
| Glucose Tolerance Test | 2 | 2018 | 228 | 0.240 |
Why?
|
| Pancreatic Polypeptide-Secreting Cells | 2 | 2013 | 5 | 0.230 |
Why?
|
| Chicago | 2 | 2021 | 1379 | 0.230 |
Why?
|
| North America | 2 | 2018 | 180 | 0.230 |
Why?
|
| Diabetic Neuropathies | 1 | 2023 | 40 | 0.230 |
Why?
|
| Body Mass Index | 2 | 2019 | 770 | 0.230 |
Why?
|
| Polyneuropathies | 1 | 2023 | 27 | 0.230 |
Why?
|
| Tetrabenazine | 3 | 2008 | 3 | 0.220 |
Why?
|
| Glucagon-Secreting Cells | 3 | 2018 | 25 | 0.220 |
Why?
|
| Rats, Inbred Lew | 7 | 2016 | 186 | 0.220 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 1673 | 0.220 |
Why?
|
| Transplantation, Heterologous | 2 | 2021 | 363 | 0.210 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2021 | 384 | 0.210 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 127 | 0.200 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2020 | 62 | 0.190 |
Why?
|
| Immunohistochemistry | 5 | 2015 | 1753 | 0.190 |
Why?
|
| Acute Disease | 3 | 2021 | 826 | 0.190 |
Why?
|
| Transplantation | 1 | 2020 | 39 | 0.190 |
Why?
|
| Costs and Cost Analysis | 1 | 2021 | 153 | 0.190 |
Why?
|
| Glucose | 3 | 2014 | 638 | 0.190 |
Why?
|
| Polyethylene Glycols | 2 | 2014 | 363 | 0.180 |
Why?
|
| Retrospective Studies | 4 | 2021 | 8477 | 0.180 |
Why?
|
| Ampulla of Vater | 1 | 2019 | 22 | 0.180 |
Why?
|
| Alcoholism | 1 | 2021 | 172 | 0.180 |
Why?
|
| Recurrence | 3 | 2021 | 1139 | 0.180 |
Why?
|
| Double-Blind Method | 2 | 2021 | 1823 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2014 | 1373 | 0.170 |
Why?
|
| Anxiety | 1 | 2021 | 287 | 0.170 |
Why?
|
| Aged | 9 | 2021 | 18402 | 0.170 |
Why?
|
| Tissue Donors | 2 | 2016 | 463 | 0.170 |
Why?
|
| Mice, Nude | 1 | 2021 | 790 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 1313 | 0.170 |
Why?
|
| Cell Transplantation | 2 | 2017 | 47 | 0.170 |
Why?
|
| Postoperative Complications | 2 | 2021 | 2207 | 0.170 |
Why?
|
| Organ Size | 3 | 2014 | 364 | 0.170 |
Why?
|
| Logistic Models | 2 | 2021 | 1185 | 0.170 |
Why?
|
| Absorptiometry, Photon | 1 | 2019 | 99 | 0.160 |
Why?
|
| Mice | 10 | 2021 | 11352 | 0.160 |
Why?
|
| Cohort Studies | 3 | 2021 | 2767 | 0.160 |
Why?
|
| Cellular Reprogramming | 1 | 2018 | 37 | 0.160 |
Why?
|
| Abdominal Pain | 2 | 2021 | 137 | 0.160 |
Why?
|
| Depression | 1 | 2021 | 473 | 0.150 |
Why?
|
| Cells, Cultured | 5 | 2016 | 2818 | 0.150 |
Why?
|
| Cell Differentiation | 3 | 2014 | 1458 | 0.150 |
Why?
|
| Smoking | 1 | 2021 | 609 | 0.150 |
Why?
|
| Area Under Curve | 1 | 2017 | 334 | 0.150 |
Why?
|
| Biotin | 2 | 2014 | 44 | 0.150 |
Why?
|
| Oligopeptides | 1 | 2017 | 179 | 0.140 |
Why?
|
| Neovascularization, Physiologic | 3 | 2017 | 133 | 0.140 |
Why?
|
| Sodium Compounds | 1 | 2016 | 3 | 0.140 |
Why?
|
| Aluminum Compounds | 1 | 2016 | 6 | 0.140 |
Why?
|
| Ultrafiltration | 1 | 2016 | 13 | 0.140 |
Why?
|
| Pain Management | 1 | 2017 | 127 | 0.140 |
Why?
|
| Foreign-Body Reaction | 1 | 2016 | 11 | 0.140 |
Why?
|
| Polyvinyls | 1 | 2016 | 17 | 0.140 |
Why?
|
| Transplantation, Homologous | 4 | 2013 | 996 | 0.140 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2014 | 49 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2020 | 375 | 0.140 |
Why?
|
| Flow Cytometry | 2 | 2016 | 679 | 0.140 |
Why?
|
| Positron-Emission Tomography | 2 | 2009 | 329 | 0.140 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2016 | 40 | 0.140 |
Why?
|
| Heart Transplantation | 3 | 2008 | 705 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2021 | 534 | 0.140 |
Why?
|
| Genetic Therapy | 1 | 2018 | 342 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
| ROC Curve | 1 | 2017 | 752 | 0.130 |
Why?
|
| Cell Proliferation | 4 | 2016 | 1578 | 0.130 |
Why?
|
| Hospitalization | 1 | 2021 | 849 | 0.130 |
Why?
|
| Pancreatic Ducts | 1 | 2014 | 26 | 0.130 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2014 | 29 | 0.130 |
Why?
|
| Pentanoic Acids | 1 | 2014 | 6 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 541 | 0.130 |
Why?
|
| Biomarkers | 3 | 2016 | 1718 | 0.120 |
Why?
|
| Incidence | 1 | 2019 | 1577 | 0.120 |
Why?
|
| Laparoscopy | 1 | 2021 | 754 | 0.120 |
Why?
|
| Pancreatic Hormones | 1 | 2014 | 15 | 0.120 |
Why?
|
| Surface-Active Agents | 1 | 2014 | 59 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2010 | 559 | 0.120 |
Why?
|
| Glucose Intolerance | 1 | 2014 | 96 | 0.120 |
Why?
|
| Receptors, Immunologic | 3 | 2018 | 135 | 0.120 |
Why?
|
| Graft Rejection | 4 | 2010 | 1065 | 0.120 |
Why?
|
| Contraindications | 1 | 2014 | 72 | 0.120 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6501 | 0.120 |
Why?
|
| Protein Precursors | 1 | 2014 | 143 | 0.120 |
Why?
|
| Tissue Engineering | 2 | 2017 | 181 | 0.120 |
Why?
|
| Hormone Replacement Therapy | 1 | 2014 | 77 | 0.110 |
Why?
|
| Serum | 1 | 2013 | 25 | 0.110 |
Why?
|
| Uracil | 1 | 2013 | 72 | 0.110 |
Why?
|
| Morphogenesis | 1 | 2014 | 192 | 0.110 |
Why?
|
| Thiazolidinediones | 1 | 2013 | 82 | 0.110 |
Why?
|
| Body Weight | 1 | 2014 | 459 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 190 | 0.110 |
Why?
|
| RNA, Messenger | 3 | 2008 | 1981 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 196 | 0.100 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2011 | 7 | 0.100 |
Why?
|
| Prognosis | 2 | 2018 | 3675 | 0.100 |
Why?
|
| Child, Preschool | 2 | 2016 | 3611 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2010 | 1208 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2014 | 482 | 0.100 |
Why?
|
| Piperidines | 1 | 2013 | 181 | 0.100 |
Why?
|
| Vesicular Monoamine Transport Proteins | 2 | 2008 | 3 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2013 | 1204 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2013 | 458 | 0.100 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2010 | 30 | 0.090 |
Why?
|
| Mice, SCID | 3 | 2018 | 252 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 1920 | 0.090 |
Why?
|
| Portal System | 1 | 2009 | 13 | 0.090 |
Why?
|
| Transplantation, Isogeneic | 1 | 2009 | 39 | 0.090 |
Why?
|
| Biomedical Engineering | 1 | 2009 | 20 | 0.090 |
Why?
|
| In Vitro Techniques | 1 | 2011 | 989 | 0.090 |
Why?
|
| Patient Selection | 1 | 2014 | 685 | 0.090 |
Why?
|
| Nanostructures | 1 | 2010 | 77 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 879 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2011 | 751 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2601 | 0.090 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 286 | 0.090 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2008 | 9 | 0.080 |
Why?
|
| Rats, Mutant Strains | 1 | 2007 | 23 | 0.080 |
Why?
|
| Injections, Intra-Arterial | 1 | 2007 | 33 | 0.080 |
Why?
|
| Ki-67 Antigen | 1 | 2007 | 64 | 0.080 |
Why?
|
| Neutrophils | 1 | 2009 | 307 | 0.080 |
Why?
|
| Rats, Inbred Strains | 1 | 2007 | 312 | 0.080 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2007 | 66 | 0.080 |
Why?
|
| Fibrin | 1 | 2007 | 84 | 0.080 |
Why?
|
| Lymphocytes | 1 | 2009 | 464 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 2262 | 0.070 |
Why?
|
| Colitis, Ulcerative | 1 | 2013 | 711 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1219 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 689 | 0.070 |
Why?
|
| Pancreas Transplantation | 1 | 2007 | 103 | 0.070 |
Why?
|
| Muscle, Smooth | 1 | 2007 | 354 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2010 | 2705 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 1685 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 2232 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 1384 | 0.070 |
Why?
|
| Biocompatible Materials | 2 | 2017 | 193 | 0.070 |
Why?
|
| Canada | 1 | 2006 | 204 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2016 | 3241 | 0.070 |
Why?
|
| Cell Adhesion | 2 | 2017 | 420 | 0.060 |
Why?
|
| Actins | 1 | 2007 | 451 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 1 | 2004 | 139 | 0.060 |
Why?
|
| Neuropeptides | 1 | 2004 | 112 | 0.060 |
Why?
|
| Vitamin A | 1 | 2023 | 27 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2018 | 3092 | 0.060 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2003 | 66 | 0.060 |
Why?
|
| Neural Conduction | 1 | 2023 | 69 | 0.060 |
Why?
|
| Thinness | 1 | 2023 | 43 | 0.060 |
Why?
|
| Mice, Inbred NOD | 2 | 2016 | 187 | 0.060 |
Why?
|
| Membrane Transport Proteins | 1 | 2004 | 166 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2007 | 663 | 0.060 |
Why?
|
| Vitamins | 1 | 2023 | 81 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 112 | 0.060 |
Why?
|
| Tissue Survival | 2 | 2014 | 13 | 0.050 |
Why?
|
| Microscopy, Confocal | 2 | 2016 | 268 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 2008 | 849 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2003 | 272 | 0.050 |
Why?
|
| Financing, Organized | 1 | 2020 | 12 | 0.050 |
Why?
|
| Pancreatic Diseases | 1 | 2020 | 52 | 0.050 |
Why?
|
| Internationality | 1 | 2020 | 69 | 0.050 |
Why?
|
| Research Personnel | 1 | 2020 | 67 | 0.050 |
Why?
|
| Placebos | 1 | 2020 | 218 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2003 | 425 | 0.040 |
Why?
|
| Gene Expression | 2 | 2014 | 1284 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 1991 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2020 | 303 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 223 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 114 | 0.040 |
Why?
|
| Alloxan | 1 | 2018 | 3 | 0.040 |
Why?
|
| Dependovirus | 1 | 2018 | 33 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 916 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2017 | 135 | 0.040 |
Why?
|
| Glucagon | 1 | 2018 | 111 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2014 | 712 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 2018 | 85 | 0.040 |
Why?
|
| Phenotype | 2 | 2016 | 2378 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2021 | 408 | 0.040 |
Why?
|
| Risk Factors | 2 | 2021 | 5417 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 258 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2004 | 1565 | 0.040 |
Why?
|
| Lymphocyte Subsets | 1 | 2016 | 64 | 0.040 |
Why?
|
| Absorption, Physicochemical | 1 | 2016 | 1 | 0.040 |
Why?
|
| Hyperglycemia | 1 | 2018 | 176 | 0.040 |
Why?
|
| Chemical Precipitation | 1 | 2016 | 18 | 0.040 |
Why?
|
| Charcoal | 1 | 2016 | 13 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2018 | 321 | 0.040 |
Why?
|
| Dioxoles | 1 | 2016 | 5 | 0.040 |
Why?
|
| Membranes, Artificial | 1 | 2016 | 40 | 0.040 |
Why?
|
| Self Report | 1 | 2018 | 288 | 0.040 |
Why?
|
| Length of Stay | 1 | 2019 | 700 | 0.040 |
Why?
|
| Materials Testing | 1 | 2016 | 91 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 154 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 1054 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2016 | 267 | 0.030 |
Why?
|
| Membrane Glycoproteins | 2 | 2010 | 428 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 451 | 0.030 |
Why?
|
| Pancreatic Function Tests | 1 | 2015 | 7 | 0.030 |
Why?
|
| Somatostatin-Secreting Cells | 1 | 2015 | 7 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2018 | 429 | 0.030 |
Why?
|
| Benzamides | 1 | 2016 | 229 | 0.030 |
Why?
|
| Myocardium | 1 | 2017 | 529 | 0.030 |
Why?
|
| Carbocyanines | 1 | 2014 | 18 | 0.030 |
Why?
|
| Succinimides | 1 | 2014 | 13 | 0.030 |
Why?
|
| Streptavidin | 1 | 2014 | 14 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 70 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 740 | 0.030 |
Why?
|
| Rats, Inbred WF | 2 | 2004 | 8 | 0.030 |
Why?
|
| Rats, Inbred ACI | 2 | 2004 | 25 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 782 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 969 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 79 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 310 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1849 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2018 | 536 | 0.030 |
Why?
|
| Cell Communication | 1 | 2014 | 194 | 0.030 |
Why?
|
| Ethanol | 1 | 2016 | 249 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2014 | 160 | 0.030 |
Why?
|
| Streptozocin | 1 | 2013 | 54 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2014 | 416 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2013 | 57 | 0.030 |
Why?
|
| Luciferases | 1 | 2013 | 118 | 0.030 |
Why?
|
| Swine | 1 | 2014 | 555 | 0.030 |
Why?
|
| Cell Line | 1 | 2017 | 2468 | 0.030 |
Why?
|
| Cytokines | 1 | 2016 | 776 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2013 | 303 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2013 | 268 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2016 | 409 | 0.030 |
Why?
|
| Protein Transport | 1 | 2014 | 411 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 2014 | 250 | 0.030 |
Why?
|
| Regeneration | 1 | 2013 | 143 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 1531 | 0.030 |
Why?
|
| Sirolimus | 1 | 2013 | 169 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 724 | 0.030 |
Why?
|
| Tacrolimus | 1 | 2013 | 373 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 303 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2019 | 2261 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2011 | 83 | 0.020 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2010 | 19 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2010 | 43 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 1540 | 0.020 |
Why?
|
| Immobilized Proteins | 1 | 2010 | 14 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2014 | 669 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2011 | 149 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2011 | 101 | 0.020 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2010 | 48 | 0.020 |
Why?
|
| Surface Properties | 1 | 2010 | 130 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 2062 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2010 | 67 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2010 | 103 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 937 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 236 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2501 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2011 | 256 | 0.020 |
Why?
|
| Perfusion | 1 | 2010 | 203 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2010 | 175 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 3030 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2009 | 220 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 425 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 896 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2010 | 312 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 557 | 0.020 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2008 | 14 | 0.020 |
Why?
|
| Levodopa | 1 | 2008 | 36 | 0.020 |
Why?
|
| Infant | 1 | 2015 | 3045 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 407 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1804 | 0.020 |
Why?
|
| Carbon Radioisotopes | 1 | 2006 | 35 | 0.020 |
Why?
|
| Dopamine | 1 | 2008 | 275 | 0.020 |
Why?
|
| Algorithms | 1 | 2014 | 1830 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 860 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 1538 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2006 | 179 | 0.020 |
Why?
|
| Vesicular Biogenic Amine Transport Proteins | 1 | 2004 | 2 | 0.020 |
Why?
|
| Culture Techniques | 1 | 2004 | 91 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2004 | 233 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2003 | 74 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 2003 | 81 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 504 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 2003 | 168 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 1014 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2004 | 337 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2003 | 253 | 0.010 |
Why?
|